Old retired woman sitting in front of monitor with virtual doctor analyzing x-ray on screen in front of her

Novartis inked a big value-based pricing deal for its heart failure drug Entresto with Cigna and Aetna. After peak Hep C pricing, Entresto is the entrant that’s been keeping payers up at night. Novartis’ deal with Cigna ties pricing, in part, to hospital readmissions. Company execs have, in the past, talked about bundling remote monitoring services with their products, but it seems they’re not there yet.

What drives the therapy selection test market?

View Now